Gunderson Dettmer advised Photys Therapeutics on the deal. Photys Therapeutics, a developer of phosphorylation-inducing chimeric small molecule (PHICS) medicines, announced its $75 million Series A financing...
Gunderson Dettmer advised Photys Therapeutics on the deal. Photys Therapeutics, a developer of phosphorylation-inducing chimeric small molecule (PHICS) medicines, announced its $75 million Series A financing...
You must be a Standard 1 Year member to access this content.